Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
The purpose of this study is to determine the optimal dose or doses of HM11260C, when administered once a week under the skin, to improve the control of blood sugar levels in patients with early-stage type 2 diabetes mellitus (T2DM).
Epistemonikos ID: b7d1831e1daf89563f2d94ee34e0aad7d7dfb448
First added on: Mar 26, 2024